A Phase II Study of Dasatinib Therapy in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or With Ph+ Leukemias Resistant or Intolerant to Imatinib
A Phase II Study of Dasatinib Therapy in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or With Ph+ Leukemias Resistant or Intolerant to Imatinib
The purpose of this study is to determine whether dasatinib is safe and effective in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia (ALL), accelerated or blast phases CML who relapse after imatinib or who are resistant or intolerant to imatinib. The side effects of this oral investigational drug in children and adolescents will be evaluated
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
Exclusion Criteria:
Other inclusion/exclusion criteria may apply
Bunos Aires, Buenos Aires 1425, Argentina
Bunos Aires, Buenos Aires 1425, Argentina
Sth Brisbane, Queensland 4101, Australia
Sth Brisbane, Queensland 4101, Australia
Df, Mexico City 06720, Mexico
Tygerberg, Western Cape 7505, South Africa
Tygerberg, Western Cape 7505, South Africa